Market Place
Sourcing Support
Olatec Therapeutics Shows Disease-Modifying Potential
20 Jan 2026 //
PR NEWSWIRE
Olatec to Conduct a Phase 2 Trial with its NLRP3 Inhibitor, Dapansutrile
20 Feb 2024 //
BUSINESSWIRE
Olatec Announces High-Impact Coverage of Dapansutrile
15 Feb 2022 //
BUSINESSWIRE
Olatec Therapeutics’ Dapansutrile, a Selective NLRP3 Inhibitor
29 Dec 2020 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.